Evidence map›Paper›PMID 38115922›Full record

ArticleHepatobiliary surgery and nutrition2023

A novel nomogram for prognosis stratification in salvage liver transplantation: a national-wide study with propensity score matching analysis in China.

Kai Wang, Fengqiang Gao, Siyi Dong, Jialu Ding, Libin Dong, Chuxiao Shao, Zhoucheng Wang, Xun Qiu, Xuyong Wei, Zhengxin Wang and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Advancing prognostic models in salvage liver transplantation.Hepatobiliary surgery and nutrition · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Kai Wang *Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Fengqiang Gao *Institute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Siyi Dong *National Center for Healthcare Quality Management in Liver Transplant, Hangzhou, China.
Jialu DingGraduate School, Nanjing University of Chinese Medicine, Nanjing, China.
Libin DongInstitute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Chuxiao ShaoDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Lishui Hospital, Zhejiang University School of Medicine, Lishui, China.
Zhoucheng WangInstitute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Xun QiuInstitute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Xuyong WeiDepartment of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhengxin WangDepartment of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Jiayin YangLiver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Qiang XiaDepartment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shusen ZhengInstitute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Xiao XuInstitute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Hangzhou First People's Hospital · CNZhejiang University · CNBlood Center of Zhejiang Province · CNFirst Affiliated Hospital Zhejiang University · CNLishui University · CNNanjing University of Chinese Medicine · CNShanghai Jiao Tong University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Salvage liver transplantation (SLT) has been reported to be an efficient treatment option for patients with recurrent hepatocellular carcinoma (HCC) after liver resection (LR). However, for recipients who underwent liver transplantation (LT) due to recurrent HCC after LR in China, the selection criteria are not well established. Methods: In this study, data from the China Liver Transplant Registry (CLTR) of 4,244 LT performed from January 2015 to December 2019 were examined, including 3,498 primary liver transplantation (PLT) and 746 SLT recipients. Propensity score matching (PSM) analysis was used to minimize between-group imbalances. The overall survival (OS) and disease-free survival (DFS) between PLT and SLT in recipients fulfilling the Milan or Hangzhou criteria were compared based on the multivariate analysis, nomograms were plotted to further classify the SLT group into low- and high-risk groups. Results: In this study, the 1-, 3- and 5-year OS and DFS of SLT recipients fulfilling Milan criteria (OS, P=0.01; DFS, P<0.001) or Hangzhou criteria (OS, P=0.03; DFS, P=0.003) were significantly reduced when compared to that of PLT group after PSM analysis. Independent risk factors, including preoperative transarterial chemoembolization (TACE), alpha fetoprotein (AFP) level, tumor maximum size and tumor total diameter were selected to draw a prognostic nomogram. The low-risk SLT recipients (1-year, 95.34%; 3-year, 84.26%; 5-year, 77.20%) showed a comparable OS with PLT recipients fulfilling Hangzhou criteria (P=0.107). Conclusions: An optimal nomogram model for prognosis stratification and clinical decision guidance of SLT was established. The low-risk SLT recipients based on the nomograms showed comparable survival with those fulfilling Hangzhou criteria in PLT group.

Indexed as

disease-free survival (DFS)nomogramoverall survival (OS)primary liver transplantation (PLT)Salvage liver transplantation (SLT)

Identifiers

PMID38115922
PMCPMC10727818
OpenAlexW4322703350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.